Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

NCT07553338 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Alzheimer's Disease

Interventions

DRUG: Leronlimab (700mg)

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]